Leuner K, Pantel J, Frey C, Schindowski K, Schulz K, Wegat T, Maurer K, Eckert A, Müller W E
Zafes, Biocenter, Department of Pharmacology, University of Frankfurt, Frankfurt, Germany.
J Neural Transm Suppl. 2007(72):207-15. doi: 10.1007/978-3-211-73574-9_27.
Alzheimer's disease (AD) is the most common progressive neurodegenerative disease. Today, AD affects millions of people worldwide and the number of AD cases will increase with increased life expectancy. The AD brain is marked by severe neurodegeneration like the loss of synapses and neurons, atrophy and depletion of neurotransmitter systems in the hippocampus and cerebral cortex. Recent findings suggest that these pathological changes are causally induced by mitochondrial dysfunction, increased oxidative stress and elevated apoptosis. Until now, AD cannot be diagnosed by a valid clinical method or a biomarker before the disease has progressed so far that dementia is present. Furthermore, no valid method is available to determine which patient with mild cognitive impairment (MCI) will progress to AD. Therefore, a correct diagnosis in the early stage of AD is not only of importance considering that early drug treatment is more effective but also that the psychological burden of the patients and relatives could be decreased. In this review, we discuss the potential role of elevated apoptosis, increased oxidative stress and mitochondrial dysfunction as biomarker for AD in a peripheral cell model, the lymphocytes.
阿尔茨海默病(AD)是最常见的进行性神经退行性疾病。如今,AD影响着全球数百万人,且随着预期寿命的增加,AD病例数量也将上升。AD大脑的特征是严重的神经退行性变,如突触和神经元丧失、海马体和大脑皮层中神经递质系统萎缩和耗竭。最近的研究结果表明,这些病理变化是由线粒体功能障碍、氧化应激增加和细胞凋亡增加因果诱导的。到目前为止,在疾病进展到出现痴呆之前,AD无法通过有效的临床方法或生物标志物进行诊断。此外,没有有效的方法来确定哪些轻度认知障碍(MCI)患者会进展为AD。因此,AD早期的正确诊断不仅很重要,因为早期药物治疗更有效,而且还能减轻患者及其亲属的心理负担。在这篇综述中,我们讨论了细胞凋亡增加、氧化应激增加和线粒体功能障碍作为外周细胞模型(淋巴细胞)中AD生物标志物的潜在作用。